High Free Cash Flow Stocks
EBS is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
EMERGENT BIOSOLUTIONS INC (EBS) Stock Price & Overview
NYSE:EBS • US29089Q1058
Current stock price
8.98 USD
+0.36 (+4.18%)
Last:
The current stock price of EBS is 8.98 USD. Today EBS is up by 4.18%. In the past month the price increased by 7.75%. In the past year, price increased by 86.58%.
EBS Key Statistics
52-Week Range4.445 - 14.06
Current EBS stock price positioned within its 52-week range.
1-Month Range7.74 - 8.84
Current EBS stock price positioned within its 1-month range.
- Market Cap
- 463.727M
- P/E
- 5.99
- Fwd P/E
- 17.10
- EPS (TTM)
- 1.50
- Dividend Yield
- N/A
EBS Stock Performance
Today
+4.18%
1 Week
+2.01%
1 Month
+7.75%
3 Months
-21.57%
Longer-term
6 Months -5.90%
1 Year +86.58%
2 Years +358.51%
3 Years -2.38%
5 Years -85.86%
10 Years -77.62%
EBS Stock Chart
EBS Stock Screens
EBS currently appears in the following ChartMill screener lists.
EBS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to EBS. When comparing the yearly performance of all stocks, EBS is one of the better performing stocks in the market, outperforming 83.26% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
EBS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to EBS. EBS has an average financial health and profitability rating.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
EBS Earnings
On February 26, 2026 EBS reported an EPS of -0.43 and a revenue of 148.70M. The company missed EPS expectations (-487.04% surprise) and missed revenue expectations (-32.31% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.43
Revenue Reported148.7M
EPS Surprise -487.04%
Revenue Surprise -32.31%
EBS Forecast & Estimates
6 analysts have analysed EBS and the average price target is 12.24 USD. This implies a price increase of 36.3% is expected in the next year compared to the current price of 8.98.
For the next year, analysts expect an EPS growth of -64.99% and a revenue growth -7.96% for EBS
Analysts
Analysts80
Price Target12.24 (36.3%)
EPS Next Y-64.99%
Revenue Next Year-7.96%
EBS Groups
Sector & Classification
EBS Financial Highlights
Over the last trailing twelve months EBS reported a non-GAAP Earnings per Share(EPS) of 1.5. The EPS increased by 583.87% compared to the year before.
Income Statements
Revenue(TTM)742.90M
Net Income(TTM)52.60M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 7.08% | ||
| ROA | 3.99% | ||
| ROE | 10.07% | ||
| Debt/Equity | 1.09 |
Chartmill High Growth Momentum
EPS Q2Q%-960%
Sales Q2Q%-23.63%
EPS 1Y (TTM)583.87%
Revenue 1Y (TTM)-28.81%
EBS Ownership
Ownership
Inst Owners81.03%
Shares51.64M
Float50.67M
Ins Owners1.55%
Short Float %19.05%
Short Ratio10.54
EBS Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.22 | 369.653B | ||
| AMGN | AMGEN INC | 15.53 | 188.346B | ||
| GILD | GILEAD SCIENCES INC | 15.62 | 171.971B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 110.812B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.1 | 78.867B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.37 | 42.456B | ||
| INSM | INSMED INC | N/A | 30.821B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.581B | ||
| NTRA | NATERA INC | N/A | 27.795B | ||
| BIIB | BIOGEN INC | 10.99 | 25.833B | ||
| UTHR | UNITED THERAPEUTICS CORP | 20.19 | 25.444B | ||
| MRNA | MODERNA INC | N/A | 21.686B | ||
| INCY | INCYTE CORP | 12.58 | 18.97B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EBS
Company Profile
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 900 full-time employees. The company went IPO on 2006-11-15. The company is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Company Info
IPO: 2006-11-15
EMERGENT BIOSOLUTIONS INC
300 Professional Dr
Gaithersburg MARYLAND 20879 US
CEO: Robert G. Kramer
Employees: 900
Phone: 12406313200
EMERGENT BIOSOLUTIONS INC / EBS FAQ
Can you describe the business of EMERGENT BIOSOLUTIONS INC?
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 900 full-time employees. The company went IPO on 2006-11-15. The company is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Can you provide the latest stock price for EMERGENT BIOSOLUTIONS INC?
The current stock price of EBS is 8.98 USD. The price increased by 4.18% in the last trading session.
Does EMERGENT BIOSOLUTIONS INC pay dividends?
EBS does not pay a dividend.
What is the ChartMill rating of EMERGENT BIOSOLUTIONS INC stock?
EBS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists EBS stock?
EBS stock is listed on the New York Stock Exchange exchange.
Can you provide the upcoming earnings date for EMERGENT BIOSOLUTIONS INC?
EMERGENT BIOSOLUTIONS INC (EBS) will report earnings on 2026-05-05.
What is the ownership structure of EMERGENT BIOSOLUTIONS INC (EBS)?
You can find the ownership structure of EMERGENT BIOSOLUTIONS INC (EBS) on the Ownership tab.